Seeking Alpha

Mike Trilivas » Comments » DNDN

  • Dendreon: Short Term Volatility For This Biotech Stock [View article]
    Neurochem's case is different that Dendereon's. Neurochem had sumbitted additional Data in February 2007 for their KIACTA drug and amended their NDA which cause the FDA to extend their decision to allow for a full review given the new data.
    May 08 10:54 am |Rating: 0 0 |Link to Comment
More on DNDN by Mike Trilivas
Comments by Ticker
Mike Trilivas'
Comments Stats
8 comments
Rating: 0 (0 - 0 )